This brand name is authorized in Ecuador
The drug BUCLIXIN contains one active pharmaceutical ingredient (API):
|
1
Buclizine
UNII 58FQD093NU - BUCLIZINE HYDROCHLORIDE
|
|
Buclizine is a piperazine derivative with the actions and uses of H1-receptor antagonists. It has anti-muscarinic and central sedative properties. The drug is used mainly for its antiemetic action, particularly in the prevention of motion sickness, and in the treatment of migraine in combination with analgesics. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| R06AE01 | Buclizine | R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AE Piperazine derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | Identifier(s): 04034-MAN-12-05, 5990-4-MAN-02-11 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
